|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/7072 | (2013.01) |
| C07H 19/06 | (2006.01) | ||
| C07H 19/16 | (2006.01) | ||
| A61K 31/7068 | (2013.01) | ||
| C07H 19/00 | (2013.01) | ||
| C07H 19/14 | (2006.01) | ||
| C07H 19/16 | (2013.01) | ||
| A61K 31/7064 | (2006.01) | ||
| A61K 31/7076 | (2006.01) | ||
| C07H 19/14 | (2013.01) | ||
| A61P 31/12 | (2006.01) | ||
| C07H 19/06 | (2013.01) | ||
| C07H 19/04 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| C07H 19/048 | (2006.01) | ||
| A61P 31/16 | (2018.01) | ||
| A61K 31/7068 | (2006.01) | ||
| A61P 31/04 | (2018.01) | ||
| A61K 31/7072 | (2006.01) | ||
| A61P 43/00 | (2018.01) | ||
| C07H 19/00 | (2006.01) | ||
| A61P 1/16 | (2018.01) | ||
| A61P 1/16 | (2006.01) | ||
| A61P 31/14 | (2018.01) | ||
| A61P 31/00 | (2006.01) | ||
| A61P 31/12 | (2018.01) | ||
| A61P 31/04 | (2006.01) | ||
| Y02A 50/30 | (2018.01) | ||
| A61P 31/14 | (2006.01) | ||
| A61P 31/00 | (2018.01) | ||
| C07H 19/04 | (2013.01) | ||
| A61P 31/16 | (2006.01) | ||
| C07H 19/048 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 43/00 | (2006.01) |
| (11) | Number of the document | 3521297 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19160413.1 |
| Date of filing the European patent application | 2004-04-21 | |
| (97) | Date of publication of the European application | 2019-08-07 |
| (45) | Date of publication and mention of the grant of the patent | 2021-12-22 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 47436803 P | 2003-05-30 | US |
| (72) |
CLARK, Jeremy , US
|
| (73) |
Gilead Pharmasset LLC ,
c/o Gilead Sciences, Inc.
333 Lakeside Drive, Foster City, CA 94404,
US
|
| (54) | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES |
| MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES |